Table 1 Patient characteristics
From: The effect of azithromycin on sputum inflammatory markers in bronchiectasis
AZM | Placebo | P-value | |
|---|---|---|---|
Total of patients | 43 | 40 | |
Age, mean (SD) | 59.6 (12.3) | 64.6 (9.1) | 0.051 |
Female, n (%) | 25 (63) | 28 (65) | 0.804 |
Aetiology of bronchiectasis, n (%) | 0.850 | ||
Post infectious | 15 (35) | 13 (33) | |
Idiopathic | 12 (28) | 15 (38) | |
Asthma | 7 (16) | 7 (18) | |
Auto-immune disease | 3 (7) | 2 (5) | |
Common variable immune deficiency | 1 (2) | 1 (3) | |
Primary ciliary dyskinesia | 1 (2) | 0 | |
Yellow nail syndrome | 0 | 1 (3) | |
Aspiration | 1 (2) | 0 | |
Mechanical obstruction | 1 (2) | 0 | |
Allergic bronchopulmonary aspergillosis | 1 (2) | 1 (3) | |
Alpha-1-antitrypsin deficiency | 1 (2) | 0 | |
Baseline sputum microbiology, n (%) | |||
Haemophilus influenzae | 13 (30) | 9 (23) | 0.617 |
Pseudomonas aeruginosa | 6 (14) | 6 (15) | 0.855 |
Other(s) | 24 (56) | 25 (62) | 0.874 |
No. Of exacerbations in year before study entry, median (IQR) | 4 (2) | 5 (3) | 0.318 |
No. Of exacerbations during the study, median (IQR) | 0 (1) | 2 (2) | 0.000 |
Pulmonary function tests, mean (SD) | |||
Δ (End-Start) FEV1, % pred | 4.4 (9.1) | -0.9 (12.6) | 0.046 |
Δ (End-Start) FVC, % pred | 5.5 (14.0) | -2.6 (12.6) | 0.013 |
Quality of life questionnaire’s, mean (SD) | |||
Δ (End-Start) Total score SGRQ | -11.3 (16.7) | -3.3 (15.8) | 0.057 |